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Abstract
Background: There is limited evidence that rituximab, a B cell depletion therapy, is an effective treatment for
systemic lupus erythematosus (SLE). Data on the mechanisms of B cell depletion in SLE indicate that the
combination of rituximab and belimumab may be more effective than rituximab alone. The safety and efficacy of
belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial aims to determine
whether belimumab is superior to placebo, when given 4–8 weeks after treatment with rituximab. This article
describes the statistical analysis plan for this trial as an update to the published protocol. It is written prior to the
end of patient follow-up, while the outcome of the trial is still unknown.
Design and methods: BEAT-LUPUS is a randomised, double-blind, phase II trial of 52 weeks of belimumab versus
placebo, initiated 4–8 weeks after rituximab treatment. The primary outcome is anti-dsDNA antibodies at 52 weeks
post randomisation. Secondary outcomes include lupus flares and damage, adverse events, doses of concomitant
medications, quality of life, and clinical biomarkers. We describe the trial’s clinical context, outcome measures,
sample size calculation, and statistical modelling strategy, and the supportive analyses planned to evaluate for
mediation of the treatment effect through changes in concomitant medication doses and bias from missing data.
Discussion: The analysis will provide detailed information on the safety and effectiveness of belimumab. It will be
implemented from July 2020 when patient follow-up and data collection is complete.
Trial registration: ISRCTN: 47873003. Registered on 28 November 2016.
EudracT: 2015-005543-14. Registered on 19 November 2018.
Keywords: Statistical analysis plan, Systemic lupus erythematosus , Rituximab, Belimumab, Anti-dsDNA, Flare, British
Isles Lupus Assessment Group, Causal mediation, Randomised controlled trial
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Trial summary and clinical context
Clinical background and rationale
Systemic lupus erythematosus (SLE) is a chronic sys-
temic autoimmune disease with a prevalence of 40–200
per 100,000 people, mainly affecting women of child-
bearing age. There is a substantial morbidity and mortal-
ity associated with SLE, with standardised mortality ra-
tios ranging from 2 to 5 [1]. There is also a lack of novel
treatments for patients with severe SLE. Due to the lack
of effective alternative therapies, many patients require
high-dose glucocorticoid therapy which is associated
with serious adverse effects including increased infec-
tions, cataracts, diabetes mellitus, and osteoporosis [2].
Both the disease itself and steroid exposure lead to in-
creased rates of cardiovascular disease [3].
A key objective for treatment of severe SLE is disease
remission induction and then prevention of “flare”; the
worsening of lupus signs and symptoms in one or more
systems of the body. It is expected that flares will be too
rare in this phase II trial for any difference between
treatment arms to be reliably detected, so anti-dsDNA
antibody levels, which are a sensitive marker of immune
system activity associated with flares [4], are the primary
outcome instead. Clinical flares are a secondary
outcome.
The biologic rituximab is currently the treatment of
choice for refractory cases of SLE where other treat-
ments have not succeeded, although no randomised con-
trolled trials (RCTs) have demonstrated its effectiveness
[5]. Previous studies have found that anti-dsDNA levels
can increase in a proportion of patients treated with ri-
tuximab who then flare, leading us to hypothesise two
effects of the medication: B cell depletion, which reduces
flare risk; but also increasing levels of serum B cell acti-
vating factor/B lymphocyte stimulator (BAFF/BLyS) in
certain patients, which increases the flare risk [6]. These
opposing effects may explain the lack of significant effi-
cacy found in the previous RCTs of rituximab.
Belimumab may be an effective addition to rituximab
in this context, as it reduces BAFF levels. We therefore
designed an early-phase clinical trial testing the safety
and efficacy of rituximab followed by belimumab com-
pared to rituximab alone [7]. Anti-dsDNA is a useful
surrogate outcome to provide an early indication of the
effectiveness of belimumab as an adjunct to rituximab,
as it is correlated both with BAFF as well as flare
activity.
Another marker of treatment effectiveness is a reduc-
tion in the patient’s steroid dose. Patients participating
in BEAT-LUPUS will typically be on steroids or both
steroids and immunosuppressants at the time of enrol-
ment. During the trial, patients may take the steroid
prednisolone and one immunosuppressant (either aza-
thioprine, methotrexate, or mycophenolate). In usual
care, their doctor will reduce their steroid dose if their
condition improves and increase the dose if their condi-
tion deteriorates. Doctors participating in BEAT-LUPUS
are asked to safely reduce their patient’s steroid dose if it
is over 10 mg/day following administration of rituximab
and belimumab/placebo. Differences between treatment
arms in the extent to which steroid dose is actually re-
duced, and then maintained at a lower dose, will be
partly determined by whether the treating clinician con-
siders that this is safe and tolerable based on clinical
symptoms following administration of belimumab or
placebo.
Trial objectives
The primary objective of BEAT-LUPUS is to compare
anti-dsDNA levels 52 weeks after randomisation between
a 52-week regime of either belimumab or placebo
amongst patients treated with rituximab 4–8 weeks be-
fore randomisation. Lupus flares, incidence of adverse
events, and changes in dosing of prednisolone are sec-
ondary outcomes. A supportive analysis will seek to
examine whether any observed reductions in anti-
dsDNA are mediated by changes in the prednisolone
dose during follow-up.
Study methods
Design, randomisation, outcomes, and interim stopping
rules
BEAT-LUPUS is a multicentre, phase II, randomised,
double-blind, placebo-controlled clinical trial comparing
safety and efficacy of a monthly regime of either beli-
mumab or placebo commencing 4–8 weeks after B cell
depletion therapy (rituximab). The total treatment
period (on belimumab or placebo) is 52 weeks. There
is an additional follow-up appointment at 56 weeks
and a pregnancy check at 68 weeks. Full details of the
interventions and study design are published in the
trial protocol [7].
From March 2017 to March 2019, 52 patients were re-
cruited and randomised 1:1 to receive either belimumab
or placebo for 52 weeks after completing treatment with
rituximab at one of 16 participating centres in the UK.
Follow-up ended in April 2020, with the statistical ana-
lysis starting immediately afterwards.
Randomisation was done using minimisation incorpor-
ating a random element to ensure unpredictability in
treatment allocations. Factors minimised include the
CD19 count at randomisation (< 0.01 × 109/l vs ≥ 0.01 ×
109/l) to account for variability in B cell depletion from
rituximab, which would affect response; anti-dsDNA
(positive or negative at first screen before rituximab);
and whether patients have active renal disease at their
first screen.
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The primary analysis will utilise an analysis of covari-
ance (ANCOVA) model, which will examine the treat-
ment difference at 52 weeks and test for superiority. The
measurement taken closest to 52-week follow up point
will be used, with measurements taken up to 2 months
before or after 52 weeks being eligible for inclusion in
the analysis.
No formal interim analyses will be done. An Inde-
pendent Data Monitoring Committee (IDMC) meet an-
nually to review safety data, and may recommend
stopping the trial if they judge the results are likely to
convince a broad range of clinicians that one arm is
clearly contraindicated.
Sample size calculation
Sample size calculations were performed using STATA
13 [8]. The calculation assumed that anti-dsDNA bind-
ing antibody levels are log normally distributed, assumed
that an ANCOVA model would be used to evaluate the
difference in mean log anti-dsDNA between treatment
arms at 52 weeks [9], and made additional adjustment
for expected losses to follow-up.
The standard deviation of anti-dsDNA and the correl-
ation structure were based on two sets of data: the study
of 35 participants by Carter et al. [6]; and data provided
by Professor David Isenberg of University College Hos-
pital for 67 participants before and 6months after B cell
depletion therapy.
Based on the data presented in Table 1, the standard
deviation of the final log anti-dsDNA measurements was
assumed to be 1.7, and the correlation between baseline
and final measurements was assumed to be 0.55.
Twenty-two evaluable participants per group would be
sufficient to detect a difference of 1.2 in log anti-dsDNA
at 5% significance with 80% power. We assumed that
20% of participants would fail to attend the 12-month
follow-up visit, so aimed to recruit 28 participants per
group.
The study’s power to detect a difference of 1.2 in log
anti-dsDNA is equivalent to being able to detect a differ-
ence of 232% between arms (equivalent to multiplying
by exp.(1.2)). To put this in context, Carter et al. found
that the log difference between participants who did and
did not flare was 1.928, corresponding to a 588% in-
crease in anti-dsDNA in those who flared [6].
Statistical principles
Two-sided p-values and 95% confidence intervals will be
reported for all statistical tests. There is one pre-
specified primary analysis, which will use a p-value
threshold of 5% to reject the null to ensure that the
probability of a type I error does not exceed 5%. Log
anti-dsDNA will be used to account for skewness in
anti-dsDNA measurements.
Adherance to the protocol requires that the patient re-
ceives their randomised treatment for 52 weeks, does
not exceed the pre-specified maximum doses of con-
comitant medication at enrolment, and also does not in-
crease their doses of concomitant medications during
follow up. Patients are encouraged to continue to pro-
vide follow-up measurements, even if they stop adhering
to the protocol before 52 weeks.
The percentages of patients who fully adhere to the
protocol and patients who do not adhere but do provide
a 52-week measurement will be reported. The primary
outcome analysis will be intention to treat; all patients
who provide baseline and 52-week anti-dsDNA mea-
surements will be included regardless of adherence to
the protocol. Secondary analyses of the primary outcome
will only include patients who adhered to the protocol.
Trial population
The full eligibility criteria for enrolment into BEAT-
LUPUS are listed in the published trial protocol [7] and
Additional File 1: Inclusion and exclusion criteria.
Counts of patients screened but not enrolled in the
trial and the reason for exclusion will be reported, and
recruitment to the trial will be presented by centre and
calendar month. The number of patients who withdraw
or are unwilling to continue follow-up will be reported
by the last follow-up visit attended and treatment arm.
Reasons for patient withdrawals will be tabulated by
treatment arm. The full throughput of patients from
screening to analysis will be summarised in a CON-
SORT flowchart [10].
Baseline characteristics of patients in BEAT-LUPUS
will be summarised by treatment arm (Additional File 1,
Dummy Tables). Characteristics described will include
screening anti-dsDNA, CD19 count, presence of renal
disease, age, and sex. Characteristics at randomisation
will also be reported: biomarker levels including anti-
dsDNA, CD19 levels, and current doses of concomitant
medications. Characteristics will be summarised using
means and standard deviations for (approximately)
normally distributed continuous variables, geometric
means and 95% confidence intervals for (approxi-
mately) log normally distributed continuous variables,
medians and interquartile ranges for non-normally
distributed variables, and frequencies and percentages
for categorical variables.
Table 1 Standard deviations and correlations for log anti-dsDNA
Dataset Time point Log mean Log SD Correlation
Isenberg (n = 67) Baseline 6.036 1.393
Follow-up 5.189 1.500 0.612
Carter (n = 35) Baseline 5.091 1.676
Follow-up 5.225 1.781 0.527
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Outcomes
Primary and secondary outcomes
The primary outcome measure is log anti-dsDNA anti-
body levels at 52 weeks. Secondary outcomes are as
follows:
1. Log anti-dsDNA antibody levels at 12 and 24 weeks
2. Proportion of participants with any adverse events
and proportion with any serious adverse events
3. Proportion of participants with any infections
4. Proportion of participants with any severe flare
(severe flare: a British Isles Lupus Assessment
Group (BILAG-2004) A score due to items which
are “new” or “worse” [11–13]; or, in the renal or
haematological systems, an A score due to items
that did not result in an A score last month) by 24
and 52 weeks, and time to severe flare
5. Proportion of participants with any severe flare or a
moderate flare (moderate flare: two BILAG B scores
due to items which are either “new” or “worse”; or,
in the renal or haematological systems, B scores due
to items that did not result in a B score last month)
by 24 and 52 weeks, and time to severe or moderate
flare
6. Proportion of participants with any severe flare,
moderate flare, or mild flare (mild flare: a single
BILAG B score due to items which are “new” or
“worse”; or, for the renal or haematological systems,
a B score due to items that did not result in a B
score last month) by 24 and 52 weeks, and time to
severe, moderate, or mild flare
7. Proportion of participants with any severe or
moderate flare accompanied by an increase in
concomitant lupus medication (glucocorticoids,
mycophenolate, azathioprine, or methotrexate) by
24 and 52 weeks, and time to flare
8. Systemic Lupus Erythematosus Disease Activity
Index 2000 (SLEDAI-2000) at 52 weeks [14]
9. Systemic Lupus International Collaborating Clinics/
American College of Rheumatology (SLICC/ACR)
damage index at 52 weeks [15]
10. Visual analogue scale (VAS) Subject Global
Assessment of Disease Activity (SGADA) at 52
weeks
11. Complement C3 at 52 weeks
12. Immunoglobulin levels at 52 weeks
13. Cumulative steroid and immunosuppressant doses
during treatment from randomisation to 52 weeks
14. Proportion of participants successfully reducing
their steroid dose at the time of randomisation:
decreasing their steroid dose by 50% without
flaring; if below 10 mg/day at randomisation,
reducing the steroid dose to 5 mg/day; or
discontinue steroids with stable disease
15. Proportion of participants with a prednisolone dose
≤ 7.5 mg/day at both weeks 48 and 52
16. Lupus Quality of Life (Lupus QoL), Short Form 36
Health Survey (SF-36), and EQ-5D-5 L at 52 weeks
[16–18]
17. Columbia Suicide Severity Rating Scale (C-SSRS) to
assess suicide risk at 52 weeks [19]
18. Stanford HAQ 20-item Disability Scale (HAQ) at
52 weeks [20]
Scoring and description of derived outcome measures
British Isles Lupus Assessment Group (BILAG-2004) index
The BILAG-2004 index questionnaire comprises 97
questions on lupus activity in the past 4 weeks compared
to the previous 4 weeks, divided among 9 systems of the
body [21]. Individual items are recorded either on a 0–4
ordinal scale from 0 = “not present” to 4 = “new”, or as
real numbers (e.g. systolic blood pressure). An algorithm
is then applied to determine an overall categorical score
for each system depending on which items are present
and how they are recorded; A = severe disease activity,
B =moderate disease activity, C =mild disease, D = in-
active disease but previously affected, and E = system
never involved. Additional criteria are applied to identify
A and B scores which are new manifestations of a flare
of the disease. “Severe” flare occurs if there is at least
one A score due to items which are “new” or “worse” on
the BILAG questionnaire; or, in the renal and haem-
atological systems, due to questionnaire items which
last month did not result in an A score (i.e. which
were less severe). A “moderate” flare occurs if at least
two new B scores occur which are due to items
which are “new” or “worse”, or, in the renal and
haematological systems, due to items which last
month did not result in a B score (i.e. were less se-
vere). A “mild” flare occurs if there is only one B
score which meets these conditions.
The subset of BILAG flares which are accompanied by
an increase in one of the medications used to control
the disease will also be evaluated. This allows evaluation
of only those flares that were severe enough in the clini-
cian’s judgement to modify the treatment regime.
The Systemic Lupus Erythematosus Disease Activity Index
2000 (SLEDAI-2000)
The SLEDAI Responder Index determines improvement
in lupus activity based on 24 items in 9 organs in the
previous 30 days [14]. The scores from the different sys-
tems are weighted in proportion to their hazard (i.e. cen-
tral nervous system items are weighted as twice that of
joint pain and kidney items) and combined into one final
score from 0 to 105.
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Patient global assessments of lupus activity on a 10-cm
visual analogue scale (VAS)
This VAS is a BEAT-LUPUS-specific measure of dis-
ease activity developed for this trial. Patients are pre-
sented with a line labelled 0–10, and point to the
number on the line which best matches their own as-
sessment of lupus activity in terms of lupus-
associated symptoms in the past 4 weeks (0 = not ac-
tive at all, 10 = extremely active).
The Systemic Lupus International Collaborating Clinics/
American College of Rheumatology (SLICC/ACR) damage
Index for systemic lupus erythematosus
The SLICC/ACR Damage Index (SDI) provides a meas-
ure of accumulated damage in the body since the onset
of lupus [22]. This summary score is based on damage
across 12 different organ systems. For each system, a
variety of different possible types of damage are listed,
each scoring 1 point, and for some items a score or 2 is
given if there has been more than one occurrence of the
item, and for renal failure requiring renal replacement
therapy a maximum score of 3 is given, and other renal
items no longer score. The summary score for the whole
body is the sum of all the individual scores.
LupusQoL
The LupusQol measure is a lupus-specific health-related
quality of life measure [16]. It comprises 34 questions
that each ask about effects of lupus on day-to-day phys-
ical and emotional health, body image, pain, planning,
fatigue, intimate relationship, and burden to others.
Patients answer each question on a scale from 1 =
“all of the time” to 5 = “never”. Average scores for
each domain are mapped to a 0–100 score. So long
as 50% of data items for a domain are completed, a
0–100 score will be calculated, in line with guidance
from the authors of the questionnaire [16]. The mean
score across domains is then calculated as the average
of the domain-specific scores.
The Short Form 36 Health Survey (SF-36)
The SF-36 is a survey of patient health in eight sections:
vitality, physical functioning, bodily pain, general health
perceptions, physical role functioning, emotional role
function, social role functioning, and mental health [17].
Each section has a score that is a weighted sum of the
questions in that section, directly transformed into a 0–
100 score, with lower scores indicating more disability.
Unanswered questions are excluded; the average for all
items on the scale that the respondent answered is used
instead. A standardised composite score of health is then
generated from each of the eight scores.
EQ-5D-5 L
The EQ-5D-5 L assesses the current health state across
five dimensions — mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression — with five
levels (each scored 1–5, with higher scores indicating
worse health state) [18]. EQ-5D dimension scores will be
converted to index scores using UK population values.
EQ-5D index scores range from − 1 = worse than death,
and then 0 = worst to 1 = best health state. The EQ-5D
additionally includes a visual analogue scale (EQ VAS),
which allows patients to record their overall current
health status on a scale ranging from 0 = worst to 100 =
best health state.
If any dimension score is missing, the EQ-5D index
score will be set to missing. If the entirety of one com-
ponent of the questionnaire (dimension score or VAS)
has not been completed, the associated component score
will be set to missing. If the entire questionnaire has not
been completed, both the EQ-5D index score and EQ-
5D VAS at that visit will be set to missing.
Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS questionnaire provides summary measures
of suicidal ideation and behaviour. These are strongly as-
sociated with the risk of an individual completing suicide
[19]. The ideation and behaviour sections can be scored
separately and also combined into one summary score
[23]. Ideation is scored at each visit from 1 = “wish to be
dead” to 5 = “active suicidal ideation with specific plan
and intent”; behaviour is scored from 6 = “preparatory
acts or behaviour” to 10 = “completed suicide”. Imput-
ation of missing values is not done; if any data are miss-
ing for a domain, its score is not calculated.
The Stanford HAQ 20-item Disability Scale (HAQ)
This questionnaire summarises patient disability based
on the extent of difficulty within eight domains; dressing
and grooming, arising, eating, walking, hygiene, reach,
grip, and activities [20]. The total score is the mean
score of the eight category scores. If more than two of
the categories are missing, the score is not calculated. If
only one category is missing, the mean of the other
seven category scores is used as the total score.
Statistical analysis
The results of the analyses will be reported following the
principle of the ICH E3 guidelines on the Structure and
Content of Clinical Study Reports. All analyses will be
performed using STATA 15 [8]. In addition, the primary
analysis of the primary outcome, mediation, and other
secondary analyses of the primary outcome will also be
done, and results for the primary outcome will be pre-
sented by levels of the stratifying variables adjusted for
in the primary analysis, as an exploratory subgroup
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analysis. For all analyses done using linear regression
models, diagnostic checks will be done using residual
plots and the data will be transformed and re-analysed if
necessary. The results will be presented (Additional File
1, Dummy tables).
Primary analysis of the primary outcome
A linear regression ANCOVA model will be fitted to
evaluate the difference in 52-week anti-dsDNA between
treatment arms, adjusting for CD19 count at randomisa-
tion (< 0.01 × 109/l vs ≥ 0.01 × 109/l), previous renal in-
volvement (yes/no) at screening, log anti-dsDNA levels
at screening, and also log anti-dsDNA levels measured
at randomisation. Patients who provide these measure-
ments will be included in the model and analysed ac-
cording to their randomised treatment, regardless of
treatment adherence. The model will be specified as fol-
lows, where Yi,j is the anti-dsDNA of patient j at time i:
log Y52; j
  ¼ β0 þ β1 treatment j
 þ β2 CD19 j
 
þ β3 log Y0; j
  þ β4 renal j
 
þ β4 log screenDNA j
  þ ε j
where treatmentj = 1 if belimumab and 0 if placebo, and
εij is a normal error distribution. The primary outcome
will be estimated by exp(β1) as the difference in anti-
dsDNA amongst patients randomised to belimumab
compared to the placebo group at 52 weeks, expressed
as a percentage of the average in the placebo group at
52 weeks.
Supportive analyses of the primary outcome
Analysis of log anti-dsDNA at 12 and 24 weeks
The model structure used for the primary analysis will
also be repeated with the outcome changed to log anti-
dsDNA at 12 and 24 weeks to evaluate differences be-
tween treatment arms at these time points. These ana-
lyses will be done on the intention-to-treat basis, the
same as the primary analysis.
Per-protocol repeated-measures analysis of anti-dsDNA at
52 weeks
Repeated-measures linear regression will be used to ana-
lyse the difference between arms in anti-dsDNA using
the randomisation and all follow-up measurements in
the same model. Measurements will be excluded after
the point a patient stops adhering to the protocol; either
the day after the patient fails to take their randomised
treatment as scheduled, or from the second day after
they increase the dose of one of the allowed concomitant
medications (whichever comes first). This model will es-
timate the mechanistic effect of belimumab on anti-
dsDNA.
In the model, Patient ID will be included as a random
effect to account for correlation between measurements
on the same patient at different points of follow-up. The
model for anti-dsDNA at 52 weeks, where yij is the anti-
dsDNA of patient j at time i, is:
yij ¼ β0 j þ β1 timeið Þ þ β2 timei  treatment j
 
þ β3 CD19 j
 þ β4 renal j
 
where β0j = β0 + u0j + εij, u0j ~ N(σ2u0 , 0), εij ~ N(0, σ
2),
and treatmentj = 1 if belimumab and 0 if placebo.
The average treatment difference at 52 weeks will be
estimated by β2 × 52. Log-transformation of anti-dsDNA
or fractional polynomials for the effect of time will be
considered if plots of residuals or likelihood ratio tests
indicate that these will improve the model fit.
Mediation analysis of the effect of prednisolone on anti-
dsDNA at 52 weeks
If material differences (p < 0.1) between treatment arms
are found in the cumulative prednisolone dose between
randomisation and 52 weeks, an exploratory causal me-
diation analysis will be done to evaluate the extent to
which this may mediate any effect of allocation to beli-
mumab on anti-dsDNA at 52 weeks [24]. The direct ef-
fect of belimumab (i.e. the effect of taking belimumab
instead of placebo, had the cumulative steroid dose been
the same in both conditions) and the average causal me-
diation effect (i.e. the effect of the cumulative steroid
dose patients would have taken on belimumab instead of
the dose they would have taken on placebo, had they ac-
tually taken belimumab in both conditions) will be esti-
mated using the STATA mediation package [25].
Sensitivity analysis for informative loss to follow-up
If over 10% of patients fail to provide a 52-week anti-
dsDNA measurement, a sensitivity analysis will be done
using multiple imputation to evaluate whether the pri-
mary analysis and the repeated-measures per-protocol
analysis are biased by missing data. Missing anti-dsDNA
measurements will be imputed using all variables in the
primary analysis model and data on concomitant medi-
cations, flares, and time to flare, all available anti-
dsDNA measurements from other scheduled visits, and
any anti-dsDNA measurements taken at point of flare/
withdrawal. A number of imputation datasets sufficient
to give a power reduction of < 1% compared to using
n = 100 will be produced [26]; the analysis models will
be run on each of these datasets; and estimates and con-
fidence intervals will be combined using Rubin’s rules
[27]. The concordance of results between the non-
imputation (complete case) and imputation models will
be assessed.
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Analysis of the secondary outcomes
The percentage of patients with the following character-
istics will be compared between treatment arms using
Fisher’s exact test:
I. BILAG severe flare
II. BILAG severe or moderate flare
III. BILAG severe, moderate, or mild flare
IV. BILAG severe or moderate flare which was
accompanied by an increase in one or more
concomitant medication
V. Any serious adverse event
VI. Any infection
VII. Any adverse events
VIII. Completed 52 weeks of follow-up
IX. Completed 52 weeks of treatment
For each of the SLEDAI, SLICC, VAS, C3, immuno-
globulin levels, LupusQoL, SF-36, and EQ-5D-DL, as-
sessments at 52 weeks will be compared between arms
using linear regression models which include the strati-
fying variables and the value of the variable at screening
(for the HAQ and SLICC) or randomisation (for all
others). Time to disease flare will be visually displayed
using Kaplan–Meier curves, and difference between
arms in hazard of flare will be tested using Cox models
that include the stratifying variables. For the BILAG flare
scores, an ordinal logistic regression model will also be
fitted to compare maximum disease flare severity experi-
enced during follow-up (severe, moderate, mild, or no
flare), also adjusted for the stratifying variables.
The following steroid dose summary measures will be
compared between the arms:
i) Cumulative steroid dose from randomisation to 52
weeks using a two-sample t test
ii) Proportion of participants successfully reducing
their steroid dose, using Fisher’s exact test
iii) Proportion of patients taking ≤ 7.5 mg of
prednisolone at weeks 48 and 52
The following quantities taken from the C-SSRS will
be compared between treatment arms:
i) Average C-SSRS score at 52 weeks
ii) Percentage of patients with a C-SSRS score which
increased to > 5 at any point during follow-up
For the questionnaires completed at each follow-up visit
(BILAG, VAS, and C-SSRS), if the questionnaire is not
completed at one visit, then the result from the previous
month will be carried forward for 1 month only (unless it
is missing due to withdrawal/flare since the previous visit,
in which case data captured at that point will be used).
Discussion
This update to the published protocol describes the pre-
specified statistical analysis plan for BEAT-LUPUS. By
publishing it we aim to increase transparency of the data
analysis, and demonstrate appropriate approaches for
the challenges of: evaluating lupus activity; concomitant
medications, which can vary between treatment arms
post randomisation due to the trial treatment given and
affect the primary outcome; and high expected loss to
follow-up, a common feature of trials on severe SLE. By
evaluating several measures of lupus activity, and using
up-to-date statistical techniques to evaluate mediation of
the treatment effect through changes in prednisolone
dose and bias from missing data, we will return compre-
hensive and robust information on the safety and effect-
iveness of belimumab compared to placebo.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04391-2.
Additional file 1. Inclusion and exclusion criteria for BEAT-LUPUS, and
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for the final statistical report.
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taining further administrative details.
Additional file 3. Guidelines for the Content of Statistical Analysis Plans
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